Administration of Tadalafil to Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Prospective Randomized Clinical Trial

Background Obesity promotes a state of metabolic syndrome and damages the vascular endothelium by altering lipid profile. Phosphodiesterase-5 (PDE-5) inhibitors restore NO signaling may improve metabolic parameters through a number of mechanisms. We hypothesized that daily administration of the PDE-5 inhibitor, Tadalafil will improve fasting plasma glucose (FPG), triglyceride (TG) levels and body weight, in obese diabetic patients. Methods Totally, 20 obese diabetic male patients with metabolic syndrome treated with Tadalafil 10 mg daily for 3 months. Body weight, FPG levels, and lipid profile were determined monthly. Results Treatment with Tadalafil caused a reduction in fasting glucose levels, fasting TGs, cholesterol, low-density lipoprotein (LDL), very-LDL and increased high-density lipoprotein, body weight was significantly reduced. Conclusion Tadalafil therapy improves glycemic control, lipid profile and body mass index in diabetic patients with metabolic syndrome.